alpha-indanoxybutyric acid derivatives



m-INDANOXYBUTYRIC ACID DERIVATIVES Seymour L. Shapiro, Hastings on Hudson, and Louis Freedman, Bronxville, N.Y., assignors to U.S. Vitamin & Pharmaceutical Corporation, a corporation of Delaware No Drawing. Filed Apr. 9, 1958, Ser. No. 727,260

2 Claims. (Cl. 260520) Patented Sept. 27, 1960 Suitably, the indanol or benzylated indanol is treated with ethyl a-bromobutyrate in acetone, under reflux, using potassium carbonate as the acid acceptor, and the reaction mixture is processedto yield the ethyl a-indoxybutyrate.

In turn, the ethyl u-indoxybutyrate can be saponified to afford the corresponding acid, or treated with amines to yield the corresponding amides.

The benzyl indanols and halobenzylated indanols which are initial reactants in some of the syntheses to be describedare obtained by condensation of the indanol with a benzyl halide or halobenzyl halide. (See applicants copending application, Serial No. 637,63 6, filed February 1, 1957, with co-inventor, Weinberg, for preparation of the reactant benzylated indanols.)

where R is selected from the group consisting of hydroxy (yielding the corresponding acids), alkoxy (yielding the corresponding esters), and arylalkylamino and dialkyl aminoalkylarnino (yielding the corresponding amides), and R is hydrogen, benzyl or halobenzyl.

The compounds of this invention have certain structural resemblance to the pharmacologically active steroids and alkaloids, and show broad spectrum phatmacologicalativity. For example, anti-inflammatory, choleretic, tranquilizing and hypocholesteremic effects are obtained.

' The compounds of this invention may be prepared by reaction of the indanol or the benzylated indanol with an a halobutyr ic acid derivative, condensed in aid-organicsolvent in the presence of an acid acceptor. T

I The following examples will serve to illustrate the in-' vention without limiting it thereto.

EXAMPLE 1 (0.2 r nole)of ethyl a-bromobutyrate and 27.6 g. (0.2 mole) of anhydrous potassium carbonate in ml. of acetone was stirred and heated under reflux for 4 hours. When cool, the solid was removed by filtration. The filtrate was diluted with 250 m1. of ice Water and then extracted with three ml. portions of ether. The ethereal extracts were combined, Washed with N sodium hydroxide, washed with water and then dried (anhydrous magnesium sulfate). After filtration, the ether was removed and the residue distilled. There was obtained 24 g. of ethyl u-(indan-4-oxy)butyrate, B.P. 114-118 C. at 0.2 mm.

' EXAMPLE 2 butyric acid,1B.P. 156-158 C. at 0.12 mm.

'.Analysis.Calcd. for C H N O C, 71.7; H, 8.8. Found: C, 70.9; H, 9.9; N, 9.0. V

. EXAMPLE 3 i In a manner similar to that described in Example 1, a mixture of 29.1 g. (0.13 mole) of 6-benzyl-5-indanol, 25.4

g. (0.13 mole) of ethyl a-bromobutyrate and 17.9 g. (0.13 mole) of potassium carbonate in 80 ml. of acetone was processed to yield 21.9 g. of ethyl a-(6-benzylindan-5- oxy) butyrate which boiled atl82190 C. at 0.7 mm;

' 95, 729 1957) showed 88% protection at. '50 .mg../kg.; l

3 EXAMPLE 4 In a manner similar to that described in Example 1, a mixture of 17.2 g. (0.13 mole) of S-indanol, 25.0 g. (0.13 mole) of ethyl ot-brornobutyrate and 17.7 g. (0.13 mole) of potassium carbonate in 5 ml. of acetone was processed to yield 18.4 g. of ethyl a-(indan--oxy)butyrate which boiled at 122-126 C. at 0.3 mm.

Analysis.Calcd. for C H O C, 72.6; H, 8.1. Found: C, 73.1; H, 8.3.

A solution of 3.7 g. (0.015 mole) of the ester above in 15 ml. of ,B-phenethylamine was heated under reflux for 8 hours. On fractional distillation there was obtained 4.66 g. of the ri-phenethylamide of a-(indan-5-oxy)butyric acid which boiled at 182 C. at 0.03 mm. This compound crystallized on standing, and when recrystallized from ethanol-water mixture melted at 64 C.

Analysis.--Calcd. for C21H25NO2: C, H, N,

4.3; Found: C, 78.2; H, 7.3; N, 4.2.

This compound potentiated adrenalin at 5 mg./kg. and showed anti-inflammatory properties.

EXAMPLE 5 In a manner similar to that described in Example 4, the ,B-phenyl amide of ot-(6-benzylindan-5-oxy)butyric acid, B.P. 208214 C. at 0.04 mm., was obtained from fl-phenethylamine and ethyl u-(6-benzylindan-5-oxy)butyrate.

A-nalysis.-Calcd. for C H NO C, 81.3; H, 7.6; N, 3.4. Found: C, 80.8; H, 7.0; N, 3.3.

This compound had pronounced effect as a depressant of central nervous system activity.

EXAMPLE 6 EXAMPLE 7 Ethyl a-(indan-4-oxy)butyrate, 22 g. (0.088 mole), was treated with 50 ml. of 3 N sodium hydroxide and heated under reflux for 2 hours. When cool, the solution so obtained was acidified with concentrated hydrochloric acid and the reaction mixture extracted with three 100 ml. portions of ether. On evaporation of the ether there was obtained 18.5 g. of ot-(indan-4-oxy)butyric acid which was recrystallized from hexane, M.P. 111-112 C.

Analysis.-Calcd. for C H O C, 70.9; H, 7.3. Found: C, 71.1; H, 7.2.

In a three-day test period, this compound administered orally at the level of 100 mg./kg. daily, effected a 51% reduction in the cholesterol levels of normal guinea pigs.

EXAMPLE 8 In a manner similar to that described in Example 6, ethyl 0L-(iI1d3.I1-4-OXy)bUty1'3t was reacted with dimethylaminopropylarm'ne to yield the dimethylaminopropylamide of a-(indan-4-oxy)butyric acid which boiled at 172 C. at 1 mm. v

Analysis.Calcd. for C H N O C, 71.0; H, 9.3. Found: C, 71.1; H, 9.4.

This compound was a depressant of central nervous system'activity showing 39.2% depression of motor activity when evaluated at 20 rag/kg. in rats.

Compounds which are typical of the purview of this invention are herein characterized and shown in Table I.

Table I a-INDANOXYBUTYRIC ACIDS AND DERIVATIVES The compounds herein prepared which are acids can be solubilized by formation of their salts with the nontoxic inorganic and organic bases. Alternatively, the dialkylaminoalkyl amides which are basic products can be solubilized as their salts with the non-toxic inorganic acids, or as the salts with organic acids. When formulated for therapeutic purposes it is to be understood that such forms of the compounds of this invention can also be applied as their non-toxic salts.

The new compound and its salts can be used as medicaments, for example, in the form of pharmaceutical preparations, which contain the compound or a salt thereof in admixture with a pharmaceutical organic or inorganic solid or liquid carrier suitable for oral or parenteral administration. used substances which do not react with the new compound, for example, water, gelatin, lactose, starches, magnesium stearate, talc, vegetable oils, gums, polyalkylene glycols, petroleum jelly, or another carrier known for medicaments.

The pharmaceutical preparations may be made up, for example, as tablets or in liquid form as solutions, suspensions or emulsions. If desired, they may be sterilized and/ or may contain auxiliary substances such as preserving agents, stabilizing agents, wetting agents, emulsify- For making these preparations there areing agents, salts for regulating the osmotic pressure, or butters. They may also contain other therapeuticallyactive substances. The preparations are made up by the usual methods.

It is to be understood that it is intended to cover all changes and modifications of the examples of the invention herein chosen for the purposes of illustration which do not constitute departures from the spirit and scope of the invention.

We claim:

1. The compound 2. The compound OTHER REFERENCES Kruber et 211.: Ben, 72B, 653-6 (1939). Kruber et 211.: Ben, 73B, 1175-7 (1940). Hoskin: I. Am. Chem. Soc., 78, 3121-2 (1956). 

1. THE COMPOUND
 2. THE COMPOUND 